Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Fortaline Plus is a nutritional supplement developed and marketed by Dafra Pharma, primarily targeting the Sub-Saharan African market. It is formulated as a combination of fish oil and vitamin E to support general health, cognitive development, and cardiovascular function. Each capsule typically contains 500 mg of fish oil, providing essential omega-3 fatty acids, specifically eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA), alongside 10 mg of vitamin E. The product utilizes EnteriCare™ anti-reflux technology to minimize the fishy aftertaste often associated with fish oil supplements. It is recommended for a wide demographic, including children, adults, and pregnant or breastfeeding women, to support overall physiological development and well-being.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Fortaline Plus.